The NCCN Gastric Cancer Guidelines adopt the same testing approach and recommend testing at the time of diagnosis of metastatic disease or relapse, with consideration of NGS to detect actionable ERBB2 mutations in selected patients [30]. Here, ERBB2 is linked to metastatic neoplasm.